Skip to main content

TALZENNA (Pfizer Australia Pty Ltd)

Product name
TALZENNA
Date registered
Evaluation commenced
Decision date
Approval time
198 working days (255)
Active ingredients
talazoparib tosilate
Registration type
NCE/NBE
Indication

TALZENNA (capsules) is indicated for the treatment of patients with a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA) mutation according to a validated diagnostic test, who have human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.

Help us improve the Therapeutic Goods Administration site